P2RX7 and graft versus host disease: Nevertheless, the current study suggests that the anti‐P2X7 mAb could be used to deplete P2X7 high cells, such as donor DCs, ex vivo prior to the transplantation of human leukocytes into NSG mice or humans (for which donor blood stem cell transplantation is indicated), with the goal of reducing GVHD severity.